Custos de implementação do cabotegravir injetável de longa duração como profilaxia ao HIV no Brasil / Costs of implementing long-acting injectable cabotegravir as HIV prophylaxis in Brazil
Paranhos, Julia; Castilho, Marta; Klein, Helena Espellet; Miranda, Caroline; Perin, Fernanda Steiner; Passoni, Patieene; Veloso, Valdiléa G.; Grinsztejn, Beatriz.
Physis (Rio J.)
; 33: e33021, 2023. tab, graf
Article
in Portuguese
|
LILACS-Express
| ID: biblio-1507041
Abstract The article describes the estimation of the potential costs, from the perspective of the Ministry of Health (MoH), of incorporating the long-acting injectable cabotegravir (CAB LA) within the Brazilian Unified Health System, as an alternative for the prevention of HIV infection and part of the national combination prevention strategy. The analytical tools of value chains were used to elaborate the CAB LA value chain by identifying its links and activities. Three demand scenarios were defined based on target population data, varying geographic scope, and potential costs were calculated. CAB LA's value chain is divided into three major links: production, incorporation, and pharmaceutical assistance. Only the latter is considered for the calculation of costs under the budgetary responsibility of the MoH. Potential costs are estimated at R$15 million, R$19 million and R$21.8 million, in low, medium, and high demand scenarios, respectively. The study presents the potential costs for the MoH, including the need for tests and procedures, to guide public managers and the incorporation process. The lack of price for CAB LA is an important limitation of the results.
Responsible library:
BR1.1
Fulltext